Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.
Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.